| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Ch55 targets retinoic acid receptors (RARs), specifically RARα, RARβ, and RARγ. Retinoic acid receptors are nuclear receptors that regulate gene transcription in response to retinoic acid. By binding to RARs, Ch55 activates the transcription of target genes involved in cell differentiation, proliferation, and apoptosis. The compound shows potent activity as a RAR agonist with selectivity for specific RAR subtypes. Its mechanism involves heterodimerization with retinoid X receptors (RXRs) and binding to retinoic acid response elements (RAREs) in target gene promoters.
|
|---|---|
| ln Vitro |
Ch55 increases dissolved sulfate levels (EC50=0.03 nM) and inhibits type I transglutaminase activity (EC50=0.02 nM) to prevent squamous cell blanking of rabbit tracheal epithelial cells. Additionally, Ch55 suppresses the induction of avian dye decarboxylase activity in 3T6 fibroblasts (EC50 = 1 nM) and stimulates secretion from cancer F9 cells and melanoma S91 cells (EC50s=0.26 and 0.5 nM) [1].
In vitro, Ch55 demonstrates potent antiproliferative and differentiating activities in various cancer cell lines. It inhibits cell growth and induces differentiation in leukemia, breast cancer, and other cancer cell types. Specific IC₅₀ values for cell growth inhibition are documented in the literature. The compound shows potent RAR agonism with high affinity for RARα, RARβ, and RARγ. It is soluble in DMSO and other organic solvents. Its activity has been characterized in cell-based assays measuring differentiation markers and cell proliferation. |
| ln Vivo |
In vivo, Ch55 has been studied in animal models of cancer and dermatological disorders. As a potent RAR agonist, it shows antiproliferative and differentiating activities that may be beneficial for the treatment of certain cancers and skin conditions. The compound's effects include inhibition of tumor growth and induction of differentiation in various tumor models. Further studies are needed to fully characterize its therapeutic potential and safety profile in vivo.
|
| Enzyme Assay |
RAR binding assays are performed using nuclear receptor preparations from cells or tissues expressing RARs. Radioligand displacement assays use [³H]-retinoic acid or other appropriate radiolabeled ligands. Ch55 is tested at various concentrations, and Ki values are calculated from competition binding curves. Transactivation assays use reporter constructs containing RAREs to measure transcriptional activation. Receptor subtype selectivity is assessed by testing against RARα, RARβ, and RARγ.
|
| Cell Assay |
In vitro cellular assays use various cancer cell lines including leukemia, breast cancer, and other cell types. Cells are treated with Ch55 at various concentrations. Cell proliferation is measured by MTT assay or cell counting. Differentiation is assessed by measuring differentiation markers using flow cytometry or Western blot. Apoptosis is evaluated by Annexin V staining or caspase activity assays. Gene expression changes are analyzed by RT-qPCR. The compound is dissolved in DMSO for stock solutions and diluted in culture media.
|
| Animal Protocol |
In vivo efficacy is evaluated in murine xenograft models using various cancer cell lines. Ch55 is administered orally, intraperitoneally, or subcutaneously. Tumor growth is monitored by caliper measurements. Endpoints include tumor volume, tumor weight, survival, and histopathological analysis. Differentiation and apoptosis markers are assessed in tumor tissues. Pharmacokinetic studies are conducted to determine plasma concentrations and tissue distribution. The compound's effects in dermatological models may also be evaluated.
|
| ADME/Pharmacokinetics |
Ch55 is a synthetic retinoid with a specific chemical structure. Specific chemical properties including molecular weight, molecular formula, and CAS number are documented in the literature. The compound is typically stored at -20°C and protected from light. It is soluble in DMSO and other organic solvents. Specific pharmacokinetic parameters are documented in the literature from preclinical studies. It is metabolized in the liver and excreted primarily in urine and feces.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Ch55 are documented in preclinical studies. As a retinoid, its toxicity profile is similar to other compounds in this class. Common adverse effects may include mucocutaneous dryness, hyperlipidemia, and teratogenicity. Retinoids are highly teratogenic and must not be used during pregnancy. Hepatotoxicity may occur with prolonged use. Standard laboratory safety precautions should be followed when handling this compound. It is intended for research use only and not for human therapeutic applications.
|
| References |
|
| Additional Infomation |
4-[3-(3,5-di-tert-butylphenyl)-3-oxopropyl-1-enyl]benzoic acid is a chalcone compound.
Ch55 is a synthetic retinoid and RAR agonist with potent antiproliferative and differentiating activities. It has been studied for its potential in cancer therapy and dermatological applications. Retinoids like Ch55 regulate gene expression through activation of RARs, affecting cell differentiation, proliferation, and apoptosis. The compound is used as a research tool to study retinoid signaling and as a potential lead compound for drug development. It is commercially available for research purposes only. |
| Molecular Formula |
C24H28O3
|
|---|---|
| Molecular Weight |
364.485
|
| Exact Mass |
364.204
|
| CAS # |
110368-33-7
|
| PubChem CID |
6184667
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.085g/cm3
|
| Boiling Point |
509.5ºC at 760mmHg
|
| Flash Point |
276ºC
|
| Vapour Pressure |
3.33E-11mmHg at 25°C
|
| Index of Refraction |
1.574
|
| LogP |
5.875
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
27
|
| Complexity |
531
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)(C)C1=CC(=CC(=C1)C(=O)/C=C/C2=CC=C(C=C2)C(=O)O)C(C)(C)C
|
| InChi Key |
FOUVTBKPJRMLPE-FMIVXFBMSA-N
|
| InChi Code |
InChI=1S/C24H28O3/c1-23(2,3)19-13-18(14-20(15-19)24(4,5)6)21(25)12-9-16-7-10-17(11-8-16)22(26)27/h7-15H,1-6H3,(H,26,27)/b12-9+
|
| Chemical Name |
4-[(E)-3-(3,5-ditert-butylphenyl)-3-oxoprop-1-enyl]benzoic acid
|
| Synonyms |
Ch 55 Ch-55 Ch55
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~137.18 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.86 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7436 mL | 13.7178 mL | 27.4356 mL | |
| 5 mM | 0.5487 mL | 2.7436 mL | 5.4871 mL | |
| 10 mM | 0.2744 mL | 1.3718 mL | 2.7436 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
